🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 12 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 20/11/2017 | 146,92 | 147,46 | 143,43 | 144,64 | -1,88% | 2,74% | 1.451.600 |
| 17/11/2017 | 147,70 | 148,79 | 146,65 | 147,41 | -0,36% | 1,45% | 903.600 |
| 16/11/2017 | 148,77 | 150,33 | 147,75 | 147,94 | -0,48% | 1,73% | 1.516.400 |
| 15/11/2017 | 147,29 | 151,75 | 146,30 | 148,66 | +0,57% | 3,70% | 1.086.600 |
| 14/11/2017 | 147,40 | 149,05 | 145,42 | 147,82 | -0,14% | 2,46% | 1.209.100 |
| 13/11/2017 | 147,44 | 148,73 | 146,25 | 148,03 | -0,48% | 1,68% | 743.600 |
| 10/11/2017 | 148,26 | 149,27 | 146,10 | 148,74 | +0,38% | 2,14% | 861.000 |
| 09/11/2017 | 146,26 | 148,50 | 144,32 | 148,17 | +0,52% | 2,86% | 1.132.400 |
| 08/11/2017 | 151,51 | 152,00 | 146,69 | 147,40 | -2,58% | 3,50% | 1.191.700 |
| 07/11/2017 | 149,03 | 151,34 | 148,32 | 151,31 | +1,56% | 2,03% | 1.385.000 |
| 06/11/2017 | 148,17 | 150,59 | 146,83 | 148,98 | -0,66% | 2,54% | 1.608.300 |
| 03/11/2017 | 143,05 | 150,08 | 142,99 | 149,97 | +3,50% | 4,96% | 1.884.900 |
| 02/11/2017 | 142,01 | 146,51 | 142,01 | 144,90 | +1,59% | 3,17% | 2.050.000 |
| 01/11/2017 | 147,35 | 147,35 | 142,39 | 142,63 | -2,46% | 3,37% | 2.412.600 |
| 31/10/2017 | 149,34 | 149,34 | 141,82 | 146,23 | -2,21% | 5,04% | 2.457.100 |
| 30/10/2017 | 149,71 | 152,80 | 148,87 | 149,53 | -0,39% | 2,63% | 1.750.500 |
| 27/10/2017 | 141,41 | 150,15 | 141,02 | 150,11 | +4,42% | 6,46% | 2.747.600 |
| 26/10/2017 | 144,88 | 147,43 | 139,05 | 143,76 | -2,07% | 5,78% | 3.735.300 |
| 25/10/2017 | 150,08 | 151,09 | 146,08 | 146,80 | -2,85% | 3,34% | 2.389.000 |
| 24/10/2017 | 151,06 | 152,87 | 148,34 | 151,11 | +0,03% | 3,00% | 1.829.600 |
| 23/10/2017 | 155,32 | 155,35 | 150,68 | 151,06 | -2,31% | 3,01% | 1.552.200 |
| 20/10/2017 | 154,97 | 155,85 | 152,60 | 154,63 | +0,02% | 2,10% | 1.320.400 |
| 19/10/2017 | 154,57 | 155,79 | 152,42 | 154,60 | -0,10% | 2,18% | 1.308.800 |
| 18/10/2017 | 155,29 | 158,04 | 154,02 | 154,76 | -0,19% | 2,59% | 1.050.400 |
| 17/10/2017 | 154,55 | 156,00 | 154,02 | 155,05 | +0,23% | 1,28% | 795.400 |
| 16/10/2017 | 153,11 | 157,78 | 153,10 | 154,70 | +1,17% | 3,06% | 2.328.400 |
| 13/10/2017 | 155,00 | 155,49 | 152,68 | 152,91 | -0,69% | 1,81% | 930.100 |
| 12/10/2017 | 152,93 | 154,85 | 152,84 | 153,98 | -0,03% | 1,31% | 1.535.000 |
| 11/10/2017 | 153,85 | 154,64 | 151,65 | 154,02 | -0,32% | 1,94% | 1.757.600 |
| 10/10/2017 | 155,19 | 156,23 | 153,50 | 154,52 | -0,66% | 1,76% | 1.055.500 |